California Stem Cell Agency Symposium: 'Vague Fears' vs. Potential Genetic Alteration of Human Race
By David Jensen,
California Stem Cell Report
| 06. 11. 2015
[Quotes CGS's Marcy Darnovsky]
Untitled Document
California’s $3 billion stem cell agency has called a high-level meeting for next fall to examine a "red-hot" issue that many prominent researchers say could lead ultimately to alteration of the human race.
The topic is a technique that makes it much easier to alter the genetic make-up of individuals in a way that can be inherited by their offspring.
In April, scientists in China reported genetically modifying human embryos in what was regarded as a “world first.” (See
here and
here.)
More recently
Marcy Darnovsky, executive director of the
Center for Genetics and Society in Berkeley,
wrote on May 28 about how the subject was viewed at a meeting called, “Biotech and the Ethical Imagination: A Global Summit.”
“The far end of techno-enthusiastic perspectives, both on human germline modification specifically and on biotech in general, was represented by Harvard experimental psychologist and popular science writer Steven Pinker. In...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...